{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:59:45Z","timestamp":1789595985672,"version":"build-2803163510"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40744-025-00754-w","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T20:41:47Z","timestamp":1744231307000},"page":"435-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects"],"prefix":"10.1007","volume":"12","author":[{"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"1","key":"754_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","volume":"8","author":"L Huangfu","year":"2023","unstructured":"Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduct Target Ther. 2023;8(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"754_CR2","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.3390\/ijms21197100","volume":"21","author":"C Rafael-Vidal","year":"2020","unstructured":"Rafael-Vidal C, P\u00e9rez N, Altab\u00e1s I, Garcia S, Pego-Reigosa JM. Blocking IL-17: a promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci. 2020;21(19):7100.","journal-title":"Int J Mol Sci"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"3360310","DOI":"10.1155\/2023\/3360310","volume":"2023","author":"L Sun","year":"2023","unstructured":"Sun L, Wang L, Moore BB, et al. IL-17: balancing protective immunity and pathogenesis. J Immunol Res. 2023;2023:3360310.","journal-title":"J Immunol Res"},{"issue":"1","key":"754_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","volume":"23","author":"KHG Mills","year":"2023","unstructured":"Mills KHG. IL-17 and IL-17-producing cells in protection versus pathology. Nat Rev Immunol. 2023;23(1):38\u201354.","journal-title":"Nat Rev Immunol"},{"key":"754_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, et al. Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.","journal-title":"Front Immunol"},{"issue":"12","key":"754_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13(12):731\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"754_CR7","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","volume":"34","author":"S Karbach","year":"2014","unstructured":"Karbach S, Croxford AL, Oelze M, et al. Interleukin-17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol. 2014;34(12):2658\u201368.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"754_CR8","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","volume":"150","author":"E Rouvier","year":"1993","unstructured":"Rouvier E, Luciani MF, Matt\u00e9i MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445\u201356.","journal-title":"J Immunol"},{"key":"754_CR9","unstructured":"U.S. Food and Drug Administration. Cosentyx. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761349. Accessed October 2024."},{"key":"754_CR10","unstructured":"European Medicines Agency. Cosentyx. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx. Accessed October 2024."},{"key":"754_CR11","unstructured":"ClinicalTrials.gov. NCT04930094. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04930094. Accessed July 2024."},{"key":"754_CR12","unstructured":"ClinicalTrials.gov. NCT05767034. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05767034. Accessed July 2024."},{"key":"754_CR13","unstructured":"ClinicalTrials.gov. NCT05380453. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05380453. Accessed July 2024."},{"key":"754_CR14","unstructured":"U.S. Food and Drug Administration. Taltz. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125521. Accessed October 2024."},{"key":"754_CR15","unstructured":"European Medicines Agency. Taltz. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz. Accessed October 2024."},{"key":"754_CR16","unstructured":"European Medicines Agency. Kyntheum. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kyntheum. Accessed October 2024."},{"key":"754_CR17","unstructured":"U.S. Food and Drug Administration. Siliq. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761032. Accessed October 2024."},{"key":"754_CR18","unstructured":"ClinicalTrials.gov. NCT03957681. 2024. https:\/\/clinicaltrials.gov\/study\/NCT03957681. Accessed September 2024."},{"key":"754_CR19","unstructured":"U.S. Food and Drug Administration. Bimzelx. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761151. Accessed October 2024."},{"key":"754_CR20","unstructured":"European Medicines Agency. Bimzelx. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bimzelx. Accessed October 2024."},{"key":"754_CR21","unstructured":"ClinicalTrials.gov. NCT05623345. 2024. https:\/\/clinicaltrials.gov\/study\/NCT05623345. Accessed September 2024."},{"key":"754_CR22","unstructured":"U.S. Food and Drug Administration. Stelara. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761044. Accessed October 2024."},{"key":"754_CR23","unstructured":"European Medicines Agency. Stelara. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara. Accessed October 2024."},{"key":"754_CR24","unstructured":"U.S. Food and Drug Administration. Tremfya. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761061. Accessed October 2024."},{"key":"754_CR25","unstructured":"European Medicines Agency. Tremfya. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya. Accessed October 2024."},{"key":"754_CR26","unstructured":"U.S. Food and Drug Administration. Ilumya. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761067. Accessed October 2024."},{"key":"754_CR27","unstructured":"European Medicines Agency. Ilumetri. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri. Accessed October 2024."},{"key":"754_CR28","unstructured":"ClinicalTrials.gov. NCT04314544. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04314544. Accessed September 2024."},{"key":"754_CR29","unstructured":"ClinicalTrials.gov. NCT04991116. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04991116. Accessed September 2024."},{"key":"754_CR30","unstructured":"ClinicalTrials.gov. NCT04314531. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04314531. Accessed September 2024."},{"key":"754_CR31","unstructured":"U.S. Food and Drug Administration. Skyrizi. 2024. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761105. Accessed October 2024."},{"key":"754_CR32","unstructured":"European Medicines Agency. Skyrizi. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi. Accessed October 2024."},{"issue":"Suppl 1","key":"754_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/annrheumdis-2024-eular.1295","volume":"83","author":"IB McInnes","year":"2024","unstructured":"McInnes IB, Coates LC, Mease PJ, et al. OP0195 Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody\u00ae, in patients with active psoriatic arthritis (PSA): results from the global, randomized, double-blind, placebo-controlled phase 2 ARGO trial. Ann Rheum Dis. 2024;83(Suppl 1):154\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"754_CR34","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","volume":"15","author":"S Klint","year":"2023","unstructured":"Klint S, Feldwisch J, Gudmundsdotter L, et al. Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs. 2023;15(1):2209920.","journal-title":"MAbs"},{"issue":"1","key":"754_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004062","volume":"10","author":"SVJ Snoeck Henkemans","year":"2024","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1): e004062.","journal-title":"RMD Open"},{"issue":"1","key":"754_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-019-1885-z","volume":"21","author":"DE Furst","year":"2019","unstructured":"Furst DE, Louie JS. Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):135.","journal-title":"Arthritis Res Ther"},{"key":"754_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.723944","volume":"8","author":"SR Pennington","year":"2021","unstructured":"Pennington SR, FitzGerald O. Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis. Front Med (Lausanne). 2021;8:723944.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"754_CR38","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946\u201354.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"754_CR39","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1002\/art.24024","volume":"58","author":"AN Bennett","year":"2008","unstructured":"Bennett AN, McGonagle D, O\u2019Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413\u20138.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"754_CR40","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1136\/annrheumdis-2017-211596","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, Sepriano A, Molto A, et al. Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. Ann Rheum Dis. 2017;76(11):1823\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"754_CR41","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3899\/jrheum.201199","volume":"48","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021;48(9):1410\u20136.","journal-title":"J Rheumatol"},{"issue":"5","key":"754_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/ard-2023-224959","volume":"83","author":"ML Marques","year":"2024","unstructured":"Marques ML, Ramiro S, van Lunteren M, et al. Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis. 2024;83(5):589\u201398.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"754_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.41239","volume":"74","author":"D Simon","year":"2022","unstructured":"Simon D, Tascilar K, Kleyer A, et al. Association of structural entheseal lesions with an increased risk of progression from psoriasis to psoriatic arthritis. Arthritis Rheumatol. 2022;74(2):253\u201362.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"754_CR44","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","volume":"75","author":"D Simon","year":"2016","unstructured":"Simon D, Faustini F, Kleyer A, et al. Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis. Ann Rheum Dis. 2016;75(4):660\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"754_CR45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/acr2.11196","volume":"2","author":"AM Liphardt","year":"2020","unstructured":"Liphardt AM, Manger E, Liehr S, et al. Similar impact of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function. ACR Open Rheumatol. 2020;2(12):734\u201340.","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"754_CR46","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1136\/annrheumdis-2012-201580","volume":"72","author":"S Finzel","year":"2013","unstructured":"Finzel S, Kraus S, Schmidt S, et al. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors. Ann Rheum Dis. 2013;72(7):1176\u201381.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"754_CR47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13075-019-1938-3","volume":"21","author":"D Simon","year":"2019","unstructured":"Simon D, Kleyer A, Bayat S, et al. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients. Arthritis Res Ther. 2019;21(1):162.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"754_CR48","doi-asserted-by":"publisher","first-page":"e003880","DOI":"10.1136\/rmdopen-2023-003880","volume":"10","author":"R Noversa de Sousa","year":"2024","unstructured":"Noversa de Sousa R, Tascilar K, Corte G, et al. Metabolic and molecular imaging in inflammatory arthritis. RMD Open. 2024;10(1):e003880.","journal-title":"RMD Open"},{"issue":"2","key":"754_CR49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/rheumatology\/keac346","volume":"62","author":"K Tascilar","year":"2023","unstructured":"Tascilar K, Fagni F, Kleyer A, et al. Non-invasive metabolic profiling of inflammation in joints and entheses by multispectral optoacoustic tomography. Rheumatology (Oxford). 2023;62(2):841\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR50","doi-asserted-by":"crossref","unstructured":"Fagni F, Tascilar K, Noversa de Sousa R, et al. Unveiling metabolic similarities of entheses in patients with psoriasis and psoriatic arthritis using noninvasive in vivo molecular imaging: results from a cross-sectional exploratory study. Arthritis Rheumatol. 2024;76(9):1387\u201396.","DOI":"10.1002\/art.42917"},{"issue":"4","key":"754_CR51","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/art.42299","volume":"75","author":"E De Lorenzis","year":"2023","unstructured":"De Lorenzis E, Natalello G, Simon D, Schett G, D\u2019Agostino MA. Concepts of entheseal pain. Arthritis Rheumatol. 2023;75(4):493\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"754_CR52","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415\u201322.","journal-title":"J Nucl Med"},{"issue":"12","key":"754_CR53","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","volume":"61","author":"J Toms","year":"2020","unstructured":"Toms J, Kogler J, Maschauer S, et al. Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an (18)F-labeled FAP inhibitor. J Nucl Med. 2020;61(12):1806\u201313.","journal-title":"J Nucl Med"},{"issue":"4","key":"754_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41590-024-01774-4","volume":"25","author":"S Rauber","year":"2024","unstructured":"Rauber S, Mohammadian H, Schmidkonz C, et al. CD200(+) fibroblasts form a pro-resolving mesenchymal network in arthritis. Nat Immunol. 2024;25(4):682\u201392.","journal-title":"Nat Immunol"},{"issue":"1","key":"754_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"754_CR56","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"754_CR57","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","volume":"77","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Sch\u00f6ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"754_CR58","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"754_CR59","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2021-220964","volume":"81","author":"S Dubash","year":"2022","unstructured":"Dubash S, Alabas OA, Michelena X, et al. Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. Ann Rheum Dis. 2022;81(4):490\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"754_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002706","volume":"8","author":"SVJ Snoeck Henkemans","year":"2022","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis. RMD Open. 2022;8(2):e002706.","journal-title":"RMD Open"},{"issue":"5","key":"754_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","volume":"78","author":"LJJ van Mens","year":"2019","unstructured":"van Mens LJJ, de Jong HM, Fluri I, et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann Rheum Dis. 2019;78(5):610\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"754_CR62","first-page":"Abstract 0889","volume":"72","author":"C Ritchlin","year":"2020","unstructured":"Ritchlin C, Kivitz A, Nash P, et al. Efficacy of secukinumab treatment in patients with early psoriatic arthritis: a pooled analysis of 4 phase 3 studies. Arthritis Rheumatol. 2020;72(Suppl 10):Abstract 0889.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"754_CR63","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1016\/S2665-9913(22)00028-5","volume":"4","author":"MLM Mulder","year":"2022","unstructured":"Mulder MLM, Vriezekolk JE, van Hal TW, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial. Lancet Rheumatol. 2022;4(4):e252\u201361.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"754_CR64","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","volume":"81","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Targher G, Idolazzi L, Girolomoni G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann Rheum Dis. 2022;81(1):68\u201373.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"754_CR65","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard-2023-224148","volume":"82","author":"A Zabotti","year":"2023","unstructured":"Zabotti A, De Marco G, Gossec L, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023;82(9):1162\u201370.","journal-title":"Ann Rheum Dis"},{"key":"754_CR66","doi-asserted-by":"crossref","unstructured":"Braun J, Kiltz U, B\u00fchring B, Baraliakos X. Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. Ther Adv Musculoskelet Dis. 2021;13:1759720x211041854.","DOI":"10.1177\/1759720X211041854"},{"issue":"9","key":"754_CR67","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/ard-2023-224232","volume":"83","author":"V Navarro-Comp\u00e1n","year":"2024","unstructured":"Navarro-Comp\u00e1n V, Benavent D, Capelusnik D, et al. ASAS consensus definition of early axial spondyloarthritis. Ann Rheum Dis. 2024;83(9):1093\u20139.","journal-title":"Ann Rheum Dis"},{"key":"754_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152032","volume":"55","author":"D Benavent","year":"2022","unstructured":"Benavent D, Capelusnik D, van der Heijde D, et al. How is early spondyloarthritis defined in the literature? Results from a systematic review. Semin Arthritis Rheum. 2022;55:152032.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 10","key":"754_CR69","first-page":"Abstract 0350","volume":"72","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Mease P, Machado P, et al. The impact of age and time since diagnosis on response to treatment with secukinumab in pooled week 52 data from 4 phase 3 studies in patients with ankylosing spondylitis. Arthritis Rheumatol. 2020;72(Suppl 10):Abstract 0350.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"754_CR70","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilov\u00e1 E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"754_CR71","first-page":"129","volume":"70","author":"R Ash","year":"2011","unstructured":"Ash R, Barkham N, McGonagle DG. Long-term results of a remission induction approach to early axial spondyloarthritis. Ann Rheum Dis. 2011;70(3):129.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"754_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73(1):101\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"754_CR73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis. 2014;73(1):108\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"754_CR74","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/keac532","volume":"62","author":"D Capelusnik","year":"2023","unstructured":"Capelusnik D, Benavent D, van der Heijde D, et al. Treating spondyloarthritis early: does it matter? Results from a systematic literature review. Rheumatology (Oxford). 2023;62(4):1398\u2013409.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"754_CR75","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1136\/annrheumdis-2024-eular.2352","volume":"83","author":"D Benavent","year":"2024","unstructured":"Benavent D, Navarro-Comp\u00e1n V, Capelusnik D, Ramiro S. POS0799 Efficacy of BDMARDS in early versus established disease in axial spondyloarthritis: a meta-analysis of randomized trials. Ann Rheum Dis. 2024;83(Suppl 1):915\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"754_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105603","volume":"90","author":"D Benavent","year":"2023","unstructured":"Benavent D, Capelusnik D, Ramiro S, Navarro-Compan V. Looking through the window of opportunity in axial spondyloarthritis? Joint Bone Spine. 2023;90(6):105603.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"754_CR77","first-page":"506","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56(4):506\u201315.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"754_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103415","volume":"23","author":"C Salvarani","year":"2024","unstructured":"Salvarani C, Padoan R, Iorio L, et al. Subclinical giant cell arteritis in polymyalgia rheumatica: concurrent conditions or a common spectrum of inflammatory diseases? Autoimmun Rev. 2024;23(1):103415.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"754_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101847","volume":"37","author":"WA Schmidt","year":"2023","unstructured":"Schmidt WA. Vascular ultrasound in rheumatology practice. Best Pract Res Clin Rheumatol. 2023;37(1): 101847.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"754_CR80","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.pop.2018.02.007","volume":"45","author":"MH Pioro","year":"2018","unstructured":"Pioro MH. Primary care vasculitis: polymyalgia rheumatica and giant cell arteritis. Prim Care. 2018;45(2):305\u201323.","journal-title":"Prim Care"},{"issue":"10","key":"754_CR81","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/art.22942","volume":"56","author":"H Marzo-Ortega","year":"2007","unstructured":"Marzo-Ortega H, Rhodes LA, Tan AL, et al. Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. Arthritis Rheum. 2007;56(10):3496\u2013501.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"754_CR82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","volume":"25","author":"WA Schmidt","year":"2023","unstructured":"Schmidt WA, Dasgupta B, Sloane J, et al. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res Ther. 2023;25(1):199.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"754_CR83","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 2016;55(1):66\u201370.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.589794","volume":"7","author":"S Monti","year":"2020","unstructured":"Monti S, Bartoletti A, Bellis E, Delvino P, Montecucco C. Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med (Lausanne). 2020;7:589794.","journal-title":"Front Med (Lausanne)"},{"issue":"2 Suppl 89","key":"754_CR85","first-page":"S103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil P, Williams M, Maw WW, et al. Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S103\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 2","key":"754_CR86","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","volume":"57","author":"WA Schmidt","year":"2018","unstructured":"Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology (Oxford). 2018;57(Suppl 2):ii22\u2013ii31.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR87","doi-asserted-by":"crossref","unstructured":"Burg LC, Karakostas P, Behning C, Brossart P, Kermani TA, Sch\u00e4fer VS. Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica - a prospective cohort study. Ther Adv Musculoskelet Dis. 2023;15:1759720x221149963.","DOI":"10.1177\/1759720X221149963"},{"issue":"1","key":"754_CR88","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1093\/rheumatology\/kead189","volume":"63","author":"E De Miguel","year":"2024","unstructured":"De Miguel E, Macchioni P, Conticini E, et al. Prevalence and characteristics of subclinical giant cell arteritis in polymyalgia rheumatica. Rheumatology (Oxford). 2024;63(1):158\u201364.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"754_CR89","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/ard-2023-224768","volume":"83","author":"E De Miguel","year":"2024","unstructured":"De Miguel E, Karalilova R, Macchioni P, et al. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica. Ann Rheum Dis. 2024;83(3):335\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"754_CR90","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/rheumatology\/keac713","volume":"62","author":"AO Donskov","year":"2023","unstructured":"Donskov AO, Mackie SL, Hauge EM, et al. An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists. Rheumatology (Oxford). 2023;62(8):2797\u2013805.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152260","volume":"63","author":"AW Nielsen","year":"2023","unstructured":"Nielsen AW, Hemmig AK, de Thurah A, et al. Early referral of patients with suspected polymyalgia rheumatica - a systematic review. Semin Arthritis Rheum. 2023;63:152260.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"754_CR92","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/ard-2023-225134","volume":"83","author":"KK Keller","year":"2024","unstructured":"Keller KK, Mukhtyar CB, Nielsen AW, et al. Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group. Ann Rheum Dis. 2024;83(11):1436\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"754_CR93","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00393-024-01519-6","volume":"83","author":"WA Schmidt","year":"2024","unstructured":"Schmidt WA, Czihal M, Gernert M, et al. Recommendations for defining giant cell arteritis fast-track clinics. English version. Z Rheumatol. 2024;83(9):762\u20135.","journal-title":"English version Z Rheumatol"},{"issue":"1","key":"754_CR94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"754_CR95","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799\u2013807.","journal-title":"Ann Rheum Dis"},{"key":"754_CR96","unstructured":"Schmidt W. Polymyalgia rheumatica (PMR) und Riesenzellarteriitis (Arteriitis temporalis). In: Jung N, Mayet W, Mertens P, Meyer J, M\u00fcller O, Pfeifer., eds. Rationelle Diagnostik und Therapie in der Inneren Medizin. Munich, Germany: Elsevier, Urban & Fischer; 2019."},{"issue":"1","key":"754_CR97","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2022;41(1):19\u201331.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"754_CR98","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/MD.0000000000000033","volume":"93","author":"MA Alba","year":"2014","unstructured":"Alba MA, Garc\u00eda-Mart\u00ednez A, Prieto-Gonz\u00e1lez S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194\u2013201.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"754_CR99","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41584-020-00505-x","volume":"16","author":"D Camellino","year":"2020","unstructured":"Camellino D, Matteson EL, Buttgereit F, Dejaco C. Author correction: monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol. 2020;16(11):662.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"754_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001003","volume":"5","author":"S Monti","year":"2019","unstructured":"Monti S, \u00c1gueda AF, Luqmani RA, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open. 2019;5(2):e001003.","journal-title":"RMD Open"},{"issue":"1","key":"754_CR101","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13063-024-07905-4","volume":"25","author":"L Kreis","year":"2024","unstructured":"Kreis L, Dejaco C, Schmidt WA, N\u00e9meth R, Venhoff N, Sch\u00e4fer VS. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study. Trials. 2024;25(1):56.","journal-title":"Trials"},{"key":"754_CR102","unstructured":"ClinicalTrials.gov. NCT03892785. 2024. https:\/\/clinicaltrials.gov\/study\/NCT03892785. Accessed September 2024."},{"key":"754_CR103","unstructured":"ClinicalTrials.gov. NCT03725202. 2024. https:\/\/clinicaltrials.gov\/study\/NCT03725202. Accessed July 2024."},{"issue":"4","key":"754_CR104","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","volume":"81","author":"M Corbera-Bellalta","year":"2022","unstructured":"Corbera-Bellalta M, Alba-Rovira R, Muralidharan S, et al. Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. Ann Rheum Dis. 2022;81(4):524\u201336.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"754_CR105","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389(14):1263\u201372.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"754_CR106","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1136\/annrheumdis-2024-eular.LBA25","volume":"83","author":"D Blockmans","year":"2024","unstructured":"Blockmans D, Penn SK, Setty A, et al. LBA0001 Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2024;83(Suppl 1):232\u20133.","journal-title":"Ann Rheum Dis"},{"key":"754_CR107","unstructured":"Genentech, Inc., South San Francisco, CA. ACTEMRA\u00ae (tocilizumab) injection, for intravenous or subcutaneous use. December 2022."},{"issue":"11","key":"754_CR108","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328(11):1053\u201362.","journal-title":"JAMA"},{"issue":"6","key":"754_CR109","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial. Ann Rheum Dis. 2022;81(6):838\u201344.","journal-title":"Ann Rheum Dis"},{"key":"754_CR110","unstructured":"Sanofi-Aventis US LLC. KEVZARA (sarilumab) injection, for subcutaneous use. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761037s015lbl.pdf. Accessed January 2025."},{"key":"754_CR111","unstructured":"Kaufman MB. FDA approves sarilumab for the treatment of adults with glucocorticoid-resistant PMR. 2023. https:\/\/www.the-rheumatologist.org\/article\/fda-approves-sarilumab-for-the-treatment-of-adults-with-glucocorticoid-resistant-pmr\/2\/?singlepage=1. Accessed April 2023."},{"key":"754_CR112","unstructured":"European Medicines Agency. Kevzara. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kevzara#product-info. Accessed January 2025."},{"key":"754_CR113","unstructured":"ClinicalTrials.gov. NCT02531633. 2024. https:\/\/clinicaltrials.gov\/study\/NCT02531633. Accessed August 2024."},{"key":"754_CR114","unstructured":"ClinicalTrials.gov. NCT03827018. 2024. https:\/\/clinicaltrials.gov\/study\/NCT03827018. Accessed September 2024."},{"issue":"6","key":"754_CR115","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","volume":"5","author":"N Venhoff","year":"2023","unstructured":"Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5(6):e341\u201350.","journal-title":"Lancet Rheumatol"},{"key":"754_CR116","doi-asserted-by":"publisher","first-page":"1199059","DOI":"10.3389\/fimmu.2023.1199059","volume":"14","author":"M Zeisbrich","year":"2024","unstructured":"Zeisbrich M, Thiel J, Venhoff N. The IL-17 pathway as a target in giant cell arteritis. Front Immunol. 2024;14:1199059.","journal-title":"Front Immunol"},{"key":"754_CR117","unstructured":"Greigert H, Ramon A, Richard C, et al. Study of the role of interleukin-17 in giant cell arteritis. Arthritis Rheumatol. 2023;75(Suppl 9):Abstract 2599."},{"issue":"11","key":"754_CR118","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64(11):3788\u201398.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"754_CR119","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/cmi.2010.21","volume":"7","author":"S Xu","year":"2010","unstructured":"Xu S, Cao X. Interleukin-17 and its expanding biological functions. Cell Mol Immunol. 2010;7(3):164\u201374.","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"754_CR120","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1042\/CS20180415","volume":"133","author":"S Nadkarni","year":"2019","unstructured":"Nadkarni S, Lashin H, Hollywood J, Dasgupta B, Mason JC, Perretti M. Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk. Clin Sci (Lond). 2019;133(7):839\u201351.","journal-title":"Clin Sci (Lond)"},{"issue":"10","key":"754_CR121","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1093\/rheumatology\/keaa054","volume":"59","author":"S Nakajima","year":"2020","unstructured":"Nakajima S, Chiba A, Makiyama A, et al. Association of mucosal-associated invariant T cells with different disease phases of polymyalgia rheumatica. Rheumatology (Oxford). 2020;59(10):2939\u201346.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.795830","volume":"9","author":"JY Mimpen","year":"2021","unstructured":"Mimpen JY, Snelling SJB, Carr AJ, Dakin SG. Interleukin-17 cytokines and receptors: potential amplifiers of tendon inflammation. Front Bioeng Biotechnol. 2021;9:795830.","journal-title":"Front Bioeng Biotechnol"},{"issue":"3","key":"754_CR123","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/rheumatology\/keab506","volume":"61","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Nakagomi D, Kobayashi Y, et al. Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR\/ACR provisional classification criteria for polymyalgia rheumatica. Rheumatology (Oxford). 2022;61(3):1185\u201394.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR124","doi-asserted-by":"publisher","first-page":"27149","DOI":"10.1038\/srep27149","volume":"6","author":"NL Millar","year":"2016","unstructured":"Millar NL, Akbar M, Campbell AL, et al. IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. Sci Rep. 2016;6:27149.","journal-title":"Sci Rep"},{"key":"754_CR125","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/912562","volume":"2013","author":"SH Unizony","year":"2013","unstructured":"Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:912562.","journal-title":"Int J Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00754-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00754-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00754-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:03:57Z","timestamp":1747404237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00754-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00754-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sofia Ramiro has received research grants from AbbVie, Galapagos\/Alfasigma, Merck Sharp & Dohme, Novartis, Pfizer, UCB; consulting and\/or speaker fees from AbbVie, Eli Lilly and Company, Galapagos\/Alfasigma, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, UCB; ASAS Executive Committee member. Georg Schett has received speaker honoraria from Bristol Myers Squibb, Cabaletta, Janssen, Kyverna, Miltenyi, and Novartis. Helena Marzo-Ortega has received research grants from Janssen, Novartis, Pfizer, UCB; honoraria\/consultation fees: AbbVie, Amgen, Biogen, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda, UCB; trial participation as principal investigator for AbbVie, Biogen, Eli Lilly, Janssen, Novartis, Pfizer, UCB. She is supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR, or the (UK) Department of Health. Wolfgang A. Schmidt has received speaker honoraria from AbbVie, Amgen, Bristol Myers Squibb, Chugai, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Roche, UCB; advisory board honoraria from AbbVie, Amgen, Boehringer Ingelheim, Fresenius Kabi, GlaxoSmithKline, Novartis, Sanofi; trial participation as principal investigator for AbbVie, GlaxoSmithKline, Novartis, Sanofi. At the time of publication, his affiliation is Krankenhaus Waldfriede, Rheumatology, Berlin, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}